

Christian Hermann Ottensmeier

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8913524/christian-hermann-ottensmeier-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

208 papers	29,580 citations	57 h-index	171 g-index
249 ext. papers	35,045 ext. citations	9 avg, IF	6.17 L-index

#	Paper	IF	Citations
208	Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.. <i>Melanoma Research</i> , 2022 , 32, 103-111	3.3	0
207	Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.. <i>BMJ Open</i> , 2022 , 12, e041961	3	0
206	HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 131	12.8	0
205	Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response.. <i>Frontiers in Oncology</i> , 2022 , 12, 862694	5.3	0
204	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials.. <i>European Journal of Cancer</i> , 2022 , 166, 287-299	7.5	1
203	CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer.. <i>Frontiers in Immunology</i> , 2022 , 13, 842653	8.4	0
202	COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. <i>Nature Communications</i> , 2021 , 12, 6760	17.4	7
201	DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. <i>Frontiers in Immunology</i> , 2021 , 12, 763086	8.4	2
200	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 1530-1540	21.7	29
199	Melanoma-reactive T cells take up residence.. <i>Nature Cancer</i> , 2021 , 2, 253-255	15.4	
198	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS9138-TPS9138	2.2	
197	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. <i>Nature Immunology</i> , 2021 , 22, 1052-1063	19.1	11
196	Analysis of immune landscape in pancreatic and ileal neuroendocrine tumours demonstrates an immune cold tumour microenvironment. <i>Neuroendocrinology</i> , 2021 ,	5.6	1
195	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). <i>International Journal of Cancer</i> , 2021 , 148, 2023-2035	7.5	4
194	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. <i>BMC Cancer</i> , 2021 , 21, 761	4.8	2
193	Early-Phase Interventional Trials in Oral Cancer Prevention. <i>Cancers</i> , 2021 , 13,	6.6	1
192	CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. <i>Neuropathology and Applied Neurobiology</i> , 2021 ,	5.2	3

191	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. <i>Cancers</i> , 2021 , 13,	6.6	3
190	Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8 T cells. <i>Science Immunology</i> , 2021 , 6,	28	77
189	Novel players: tissue-resident memory B cells. <i>Blood</i> , 2020 , 136, 2722-2723	2.2	1
188	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma 2020 , 8,		9
187	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020 , 31, 107550	10.6	19
186	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 895-904	35.1	56
185	NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. <i>Cancer Research</i> , 2020 , 80, 1846-1860	10.1	81
184	Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. <i>Cell Death Discovery</i> , 2020 , 6, 54	6.9	6
183	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020 , 146, 2305-2314	7.5	19
182	Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 T Cells. <i>SSRN Electronic Journal</i> , 2020 , 3641939	1	25
181	Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF- α . <i>ELife</i> , 2020 , 9,	8.9	39
180	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors 2020 ,		11
179	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future 2020 , 761-783		1
178	Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4 T cells 2020 ,		26
177	Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 T cells 2020 ,		6
176	COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types 2020 ,		2
175	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
174	Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 T Cells in COVID-19. <i>Cell</i> , 2020 , 183, 1340-1353.e16	56.2	205

173	M1 tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer 2020 , 8,		28
172	HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. <i>Cells</i> , 2020 , 9,	7.9	16
171	CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage 2020 , 8,		10
170	Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. <i>Frontiers in Oncology</i> , 2020 , 10, 591063	5.3	
169	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2128-2149	16.6	87
168	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8 T-cell Tumor Infiltration in OPSCC. <i>Cancer Immunology Research</i> , 2019 , 7, 1202-1213	12.5	16
167	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 1255-1268	7.6	26
166	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019 , 567, 479-485	50.4	358
165	Recent advances in the molecular landscape of lung neuroendocrine tumors. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 281-297	3.8	25
164	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. <i>Onc Immunology</i> , 2019 , 8, e1593810	7.2	19
163	Recurrent group A tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T cells. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	49
162	Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. <i>Cell Death and Differentiation</i> , 2019 , 26, 943-957	12.7	49
161	Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. <i>Cell Death and Disease</i> , 2019 , 10, 591	9.8	59
160	An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. <i>Scientific Reports</i> , 2019 , 9, 9580	4.9	16
159	An Optimized Method to Isolate Human Fibroblasts from Tissue for Analysis. <i>Bio-protocol</i> , 2019 , 9, e3440.9		
158	Importance of the immune system in head and neck cancer. <i>Head and Neck</i> , 2019 , 41, 2789-2800	4.2	14
157	The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019 , 9, e031531	3	8
156	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019 , 565, 240-245	50.4	388

155	HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019 , 120, 356-367	8.7	27
154	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Onc Immunology</i> , 2018 , 7, e1433516	7.2	26
153	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. <i>Journal of Surgical Oncology</i> , 2018 , 117, 1170-1178	2.8	42
152	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. <i>Onc Immunology</i> , 2018 , 7, e1395125	7.2	19
151	Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 627-638	7.4	19
150	Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	83
149	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2018 , 19, 233	2.8	33
148	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018 , 33, 649-663.e4	24.3	296
147	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 342-353	3.4	11
146	CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e193-e196	8.9	16
145	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018 , 17, 2132-2145	7.6	16
144	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018 , 14, 2415-2431	3.6	19
143	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018 , 29, 1843-1852	10.3	33
142	Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1451-1453	10.2	38
141	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2000-2000	2.2	8
140	A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6068-6068	2.2	3
139	Immunotherapy in metastatic melanoma: When is it safe to stop?. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21518-e21518	2.2	
138	CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS8586-TPS8586	2.2	

137	BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY. <i>Retinal Cases and Brief Reports</i> , 2018 , 12, 184-187	1.1	10
136	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018 , 20, vi5-vi5	1	78
135	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. <i>Annals of Oncology</i> , 2018 , 29, viii497	10.3	10
134	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. <i>ELife</i> , 2018 , 7,	8.9	48
133	Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). <i>Journal of Clinical Oncology</i> , 2017 , 35, 1506-1514	2.2	66
132	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017 , 46, 577-586	32.3	225
131	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017 , 545, 446-451	50.4	796
130	Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. <i>Nature Immunology</i> , 2017 , 18, 940-950	19.1	258
129	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017 , 171, 1259-1271.e11	56.2	541
128	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. <i>Clinical Cancer Research</i> , 2017 , 23, 7641-7649	12.9	13
127	Towards personalised medicine in lung and thymus neuroendocrine tumours. <i>Lancet Oncology</i> , 2017 , 18, 1563-1565	21.7	1
126	Evaluating the effect of immune cells on the outcome of patients with mesothelioma. <i>British Journal of Cancer</i> , 2017 , 117, 1341-1348	8.7	35
125	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. <i>European Journal of Cancer</i> , 2017 , 87, 75-83	7.5	13
124	Novel Approaches for Vaccination Against HPV-Induced Cancers. <i>Current Topics in Microbiology and Immunology</i> , 2017 , 405, 33-53	3.3	1
123	Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS9099-TPS9099	2.2	
122	Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. <i>Current Topics in Microbiology and Immunology</i> , 2017 , 405, 123-143	3.3	6
121	Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. <i>OncolImmunology</i> , 2016 , 5, e1209615	7.2	11
120	A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer. <i>OncolImmunology</i> , 2016 , 5, e1166323	7.2	16

119	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1511-21	8.9	74
118	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 161-9	7.4	140
117	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. <i>OncolImmunology</i> , 2016 , 5, e1143997	7.2	55
116	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 212-223	21.7	110
115	Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. <i>Aging</i> , 2016 , 9, 114-132	5.6	60
114	WilmsTumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). <i>Efficacy and Mechanism Evaluation</i> , 2016 , 3, 1-80	1.7	5
113	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. <i>PLoS ONE</i> , 2016 , 11, e0155059	3.7	4
112	Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. <i>Oncotarget</i> , 2016 , 7, 56781-56797	3.3	65
111	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 651-62	7.4	67
110	Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. <i>Cancer Research</i> , 2016 , 76, 4136-48	10.1	60
109	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2016 , 22, 4827-4836	12.9	20
108	TG4010: a vaccine with a therapeutic role in cancer. <i>Immunotherapy</i> , 2016 , 8, 511-9	3.8	11
107	Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4132-4141	2.2	78
106	Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , 2015 , 113, 107-18	8.7	28
105	Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 585-98	7.4	15
104	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2015 , 64, 1021-32	7.4	21
103	Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. <i>Clinical Cancer Research</i> , 2015 , 21, 1321-8	12.9	57
102	Immunosuppression for ipilimumab-related toxicity can cause pneumonia but spare antitumor immune control. <i>OncolImmunology</i> , 2015 , 4, e1040218	7.2	30

101	Uveal Melanoma UK National Guidelines. <i>European Journal of Cancer</i> , 2015 , 51, 2404-12	7.5	59
100	NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. <i>International Journal of Cancer</i> , 2015 , 136, E590-601	7.5	33
99	Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. <i>Melanoma Research</i> , 2015 , 25, 432-42	3.3	47
98	Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. <i>PLoS ONE</i> , 2015 , 10, e0118096	3.7	51
97	Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T Cells. <i>PLoS ONE</i> , 2015 , 10, e0136717	3.7	19
96	Infliximab for IPILIMUMAB-Related Colitis-Letter. <i>Clinical Cancer Research</i> , 2015 , 21, 5642-3	12.9	39
95	Staging and treatment of oropharyngeal cancer in the human papillomavirus era. <i>Head and Neck</i> , 2015 , 37, 1002-13	4.2	38
94	An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9035-9035	2.2	0
93	Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e20000-e20000	2.2	4
92	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future 2015 , 471-490		0
91	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. <i>Annals of Oncology</i> , 2014 , 25, 968-74	10.3	53
90	Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function. <i>Journal of Pathology</i> , 2014 , 233, 196-208	9.4	6
89	The immune response in HPV oropharyngeal cancer. <i>OncolImmunology</i> , 2014 , 3, e27254	7.2	27
88	A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 2192-204	12.9	111
87	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	88
86	Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. <i>British Journal of Cancer</i> , 2014 , 110, 489-500	8.7	229
85	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. <i>Science Translational Medicine</i> , 2014 , 6, 254ra128	17.5	281
84	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 1199-211	7.4	20

83	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. <i>European Journal of Cancer</i> , 2014 , 50, 1717-1721	7.5	10
82	The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1313-20	3.6	102
81	The role of the reporting framework MIATA within current efforts to advance immune monitoring. <i>Journal of Immunological Methods</i> , 2014 , 409, 6-8	2.5	3
80	Phase I trial of ImmunoBody in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3061-3061	2.2	2
79	FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. <i>British Journal of Cancer</i> , 2013 , 109, 387-94	8.7	50
78	Genetic Vaccines against Cancer 2013 , 223-239		1
77	Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 615-27	7.4	23
76	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 489-501	7.4	15
75	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013 , 49, 2815-22	7.5	38
74	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013 , 24, 2875-80	10.3	38
73	New horizons for prostate cancer: part 2. <i>Trends in Urology & Men's Health</i> , 2013 , 4, 13-16	0.3	
72	New horizons for prostate cancer: part 1. <i>Trends in Urology & Men's Health</i> , 2013 , 4, 38-40	0.3	
71	CD8+ T-cell cross-competition is governed by peptide-MHC class I stability. <i>European Journal of Immunology</i> , 2012 , 42, 256-63	6.1	10
70	DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 2161-70	7.4	73
69	T cell assays and MIATA: the essential minimum for maximum impact. <i>Immunity</i> , 2012 , 37, 1-2	32.3	117
68	The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. <i>European Journal of Surgical Oncology</i> , 2012 , 38, 889-96	3.6	12
67	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 66	3	45
66	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012 , 10, 205	8.5	538

65	Improved survival with MEK inhibition in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , 2012 , 367, 107-14	59.2	1634
64	Harmonization of the intracellular cytokine staining assay. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 967-78	7.4	39
63	A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. <i>Chemotherapy</i> , 2012 , 58, 257-63	3.2	5
62	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS8605-TPS8605	2.2	
61	Harmonization of immune biomarker assays for clinical studies. <i>Science Translational Medicine</i> , 2011 , 3, 108ps44	17.5	81
60	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. <i>New England Journal of Medicine</i> , 2011 , 364, 2507-16	59.2	5851
59	DNA fusion vaccines enter the clinic. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 1147-51	7.4	20
58	DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. <i>European Journal of Immunology</i> , 2011 , 41, 2447-56	6.1	14
57	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011 , 105, 353-9	8.7	39
56	A randomised, phase II study of intetumumab, an anti- α -integrin mAb, alone and with dacarbazine in stage IV melanoma. <i>British Journal of Cancer</i> , 2011 , 105, 346-52	8.7	91
55	T-cell immune monitoring assays to guide the development of new cancer vaccines 2011 , 156-166		
54	Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. <i>International Immunology</i> , 2010 , 22, 875-87	4.9	32
53	Improved survival with ipilimumab in patients with metastatic melanoma. <i>New England Journal of Medicine</i> , 2010 , 363, 711-23	59.2	10591
52	Melanoma sentinel node biopsy and prediction models for relapse and overall survival. <i>British Journal of Cancer</i> , 2010 , 103, 1229-36	8.7	43
51	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 863-73	7.4	43
50	Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 619-27	7.4	26
49	Response definition criteria for ELISPOT assays revisited. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1489-501	7.4	155
48	DNA vaccines against cancer come of age. <i>Current Opinion in Immunology</i> , 2010 , 22, 264-70	7.8	59

47	Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5248-54	2.2	51
46	The synthesis and in vivo evaluation of 2',2'-difluoro KRN7000. <i>ChemMedChem</i> , 2009 , 4, 329-34	3.7	21
45	First case report of Muir-Torre syndrome associated with non-small cell lung cancer. <i>Familial Cancer</i> , 2009 , 8, 359-62	3	13
44	Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 789-800	7.4	15
43	DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. <i>Human Gene Therapy</i> , 2009 , 20, 1269-78	4.8	152
42	Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, S23-S24		1
41	Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. <i>Blood</i> , 2009 , 113, 4677-80	2.2	50
40	Survival from melanoma of the skin in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008 , 99 Suppl 1, S50-2	8.7	3
39	DNA vaccines: precision tools for activating effective immunity against cancer. <i>Nature Reviews Cancer</i> , 2008 , 8, 108-20	31.3	341
38	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. <i>Molecular Immunology</i> , 2008 , 45, 1567-72	4.3	44
37	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. <i>Lancet, The</i> , 2008 , 371, 1685-94	40	210
36	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet, The</i> , 2008 , 372, 117-126	40	496
35	Synthesis and in vivo evaluation of 4-deoxy-4,4-difluoro-KRN7000. <i>Organic Letters</i> , 2008 , 10, 4433-6	6.2	26
34	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 289-302	7.4	129
33	Synthesis and in vitro evaluation of alpha-GalCer epimers. <i>ChemMedChem</i> , 2008 , 3, 1061-70	3.7	33
32	Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. <i>Methods in Molecular Biology</i> , 2008 , 423, 497-507	1.4	12
31	Cancer Vaccines 2007 , 183-204		3
30	C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007 , 2, S359	8.9	3

29	Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. <i>Cancer Research</i> , 2006 , 66, 3996-4000	10.1	103
28	Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. <i>British Journal of Cancer</i> , 2006 , 94, 1383-8	8.7	48
27	Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?. <i>Leukemia</i> , 2006 , 20, 530-4	10.7	27
26	Idiotypic gene rescue in follicular lymphoma. <i>Methods in Molecular Medicine</i> , 2005 , 115, 145-71		1
25	DNA vaccines to attack cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101 Suppl 2, 14646-52	11.5	100
24	DNA fusion gene vaccines against cancer: from the laboratory to the clinic. <i>Immunological Reviews</i> , 2004 , 199, 156-80	11.3	70
23	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003 , 30, 136-41	5.5	28
22	Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. <i>British Journal of Haematology</i> , 2003 , 120, 217-22	4.5	51
21	Anti-idiotypic vaccines. <i>British Journal of Haematology</i> , 2003 , 123, 770-81	4.5	25
20	Vaccine therapy in NHL: future promises and current limitations. <i>Leukemia and Lymphoma</i> , 2003 , 44 Suppl 3, S85-90	1.9	2
19	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. <i>Blood</i> , 2002 , 99, 2562-8	2.2	202
18	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. <i>Blood</i> , 2002 , 100, 1505-1507	2.2	87
17	The occurrence and significance of V gene mutations in B cell-derived human malignancy. <i>Advances in Cancer Research</i> , 2001 , 83, 81-116	5.9	82
16	The classification of lymphomas and leukemias. <i>Chemico-Biological Interactions</i> , 2001 , 135-136, 653-64	5	10
15	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. <i>Blood</i> , 2000 , 96, 2550-2556	2.2	10
14	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. <i>Blood</i> , 2000 , 96, 2550-2556	2.2	
13	Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. <i>British Journal of Cancer</i> , 1999 , 81, 1213-21	8.7	10
12	Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. <i>Immunological Reviews</i> , 1998 , 162, 247-59	11.3	113

11	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. <i>Blood</i> , 1998 , 91, 4292-4299	2.2	124
10	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. <i>Blood</i> , 1998 , 91, 4292-4299	2.2	5
9	Histological transformation of indolent (follicular) lymphoma. <i>Annals of Oncology</i> , 1996 , 7, 849-53	10.3	2
8	Absence of constitutive EGF receptor activation in ovarian cancer cell lines. <i>British Journal of Cancer</i> , 1996 , 74, 446-52	8.7	16
7	CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. <i>Journal of Clinical Oncology</i> , 1995 , 13, 1912-21	2.2	72
6	Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. <i>Gynecologic Oncology</i> , 1995 , 58, 216-25	4.9	126
5	Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. <i>Annals of Hematology</i> , 1991 , 63, 1-4	3	72
4	T FR Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. <i>SSRN Electronic Journal</i> ,	1	1
3	Evidence that recurrent Group A streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant Tfh cells		1
2	Interplay of Monocytes and T Lymphocytes in COVID-19 Severity		6
1	Immunomodulatory effects of PI3K inhibition in solid tumors Evaluation in a randomized phase II trial		2